Migraine with aura versus migraine without aura: Pain intensity and associated symptom intensities after placebo

Headache

Volumn 42, Issue 9, 2002, Pages 872-877

  Bigal, Marcelo E ^a,c,d   Bordini, Carlos A ^b   Sheftell, Fred D ^a   Speciali, José G ^b   Bigal, Janaína O M ^a,c  

^a NEW ENGLAND CENTER FOR HEADACHE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF RIBEIRÃO PRETO   (Brazil)

^d The New England Center of Headache   (United States)

Author keywords

Migraine with aura; Migraine without aura; Placebo; Stratification

Indexed keywords

CHLORPROMAZINE; DICLOFENAC; DIPYRONE; MAGNESIUM SULFATE; PLACEBO;

ADULT; ANALGESIA; ARTICLE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MIGRAINE WITH AURA; NAUSEA; PAIN ASSESSMENT; PHONOPHOBIA; PHOTOPHOBIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; VISUAL ANALOG SCALE;

ADULT; BIAS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; PAIN MEASUREMENT; PLACEBOS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 0036803715     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-4610.2002.02205.x     Document Type: Article

References (17)

1. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia. 1991;11:1-12.
2. Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neufol. 1991;31:295-299.
3. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine: Second edition. Cephalalgia. 2000;20:765-786.
4. Dechant KL, Clissod SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992;43:776-798.
5. Bigal ME, Bordini CA, Speciali JG. Efficacy of four drugs in the acute treatment of migraine with aura and migraine without aura. A double blind study. Arq Neuropsiquiatr. 2002;60.
6. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders cranial neuralgia and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
7. Von-Korff M, Stewart WF, Lipton RB. Assessing headache severity. New directions. Neurology. 1994; 44 (suppl 4):40-46.
8. Lipton RB, Stewart WF, Ryan RE, Jr., Saper J, Sheftell F. Efficacy and safety of acetaminophen, aspirin and caffeine in alleviating migraine headache pain: Three double-blind, randomized, placebo controlled trials. Arch Neurol. 1998;55:210-217.
9. Silverman WA, Chalmers I. Sir Austin Bradford Hill: An appreciation. Contr Clin Trials. 1992;13:100-105.
10. Jadad AR, Rennie D. The randomized controlled trials gets a middle-aged checkup. JAMA. 1998;279:319-320.
11. Altmann DG, ed. Practical Statistics for Medical Research. London: Chapman & Hall; 1991:84-92.
12. Mosteller F, Gilbert JP, Mcpeek B. Reporting standards and research strategies for controlled trials: Agenda for the editor. Contr Clin Trials. 1980;1:37-58.
13. Sackett DL. Bias in analytic research. J Chronic Dis. 1979;32:51-53.
14. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242-1245.
15. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Headache. 1998;38:748-755.
16. The Diclofenac-K/Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. Cephalalgia. 1999;19:232-242.
17. Tfelt-Hansen P. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia. 1998;18:532-538.